Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15


The Role of MDM2 in Promoting Genome Stability versus Instability.

Saadatzadeh MR, Elmi AN, Pandya PH, Bijangi-Vishehsaraei K, Ding J, Stamatkin CW, Cohen-Gadol AA, Pollok KE.

Int J Mol Sci. 2017 Oct 23;18(10). pii: E2216. doi: 10.3390/ijms18102216. Review.


Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment.

Yee-Lin V, Pooi-Fong W, Soo-Beng AK.

Mini Rev Med Chem. 2018;18(2):173-183. doi: 10.2174/1389557517666170717125821. Review.


Inhibitors of ubiquitin E3 ligase as potential new antimalarial drug leads.

Jain J, Jain SK, Walker LA, Tekwani BL.

BMC Pharmacol Toxicol. 2017 Jun 2;18(1):40. doi: 10.1186/s40360-017-0147-4.


Inhibition of the p53/hDM2 protein-protein interaction by cyclometallated iridium(III) compounds.

Liu LJ, He B, Miles JA, Wang W, Mao Z, Che WI, Lu JJ, Chen XP, Wilson AJ, Ma DL, Leung CH.

Oncotarget. 2016 Mar 22;7(12):13965-75. doi: 10.18632/oncotarget.7369.


USP15 stabilizes MDM2 to mediate cancer-cell survival and inhibit antitumor T cell responses.

Zou Q, Jin J, Hu H, Li HS, Romano S, Xiao Y, Nakaya M, Zhou X, Cheng X, Yang P, Lozano G, Zhu C, Watowich SS, Ullrich SE, Sun SC.

Nat Immunol. 2014 Jun;15(6):562-70. doi: 10.1038/ni.2885. Epub 2014 Apr 28.


5-Deazaflavin derivatives as inhibitors of p53 ubiquitination by HDM2.

Dickens MP, Roxburgh P, Hock A, Mezna M, Kellam B, Vousden KH, Fischer PM.

Bioorg Med Chem. 2013 Nov 15;21(22):6868-77. doi: 10.1016/j.bmc.2013.09.038. Epub 2013 Sep 25.


Targeting the ubiquitin-proteasome system for cancer therapy.

Shen M, Schmitt S, Buac D, Dou QP.

Expert Opin Ther Targets. 2013 Sep;17(9):1091-108. doi: 10.1517/14728222.2013.815728. Epub 2013 Jul 4. Review.


Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy.

Devine T, Dai MS.

Curr Pharm Des. 2013;19(18):3248-62. Review.


HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas.

Sosin AM, Burger AM, Siddiqi A, Abrams J, Mohammad RM, Al-Katib AM.

J Hematol Oncol. 2012 Sep 18;5:57. doi: 10.1186/1756-8722-5-57.


The Fbw7 and betaTRCP E3 ubiquitin ligases and their roles in tumorigenesis.

Lau AW, Fukushima H, Wei W.

Front Biosci (Landmark Ed). 2012 Jun 1;17:2197-212. Review.


Functional analysis and consequences of Mdm2 E3 ligase inhibition in human tumor cells.

Wade M, Li YC, Matani AS, Braun SM, Milanesi F, Rodewald LW, Wahl GM.

Oncogene. 2012 Nov 8;31(45):4789-97. doi: 10.1038/onc.2011.625. Epub 2012 Jan 23.


MDM2 promotes SUMO-2/3 modification of p53 to modulate transcriptional activity.

Stindt MH, Carter S, Vigneron AM, Ryan KM, Vousden KH.

Cell Cycle. 2011 Sep 15;10(18):3176-88. Epub 2011 Sep 15.


RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis.

Lipkowitz S, Weissman AM.

Nat Rev Cancer. 2011 Aug 24;11(9):629-43. doi: 10.1038/nrc3120. Review.


N-acylpolyamine inhibitors of HDM2 and HDMX binding to p53.

Hayashi R, Wang D, Hara T, Iera JA, Durell SR, Appella DH.

Bioorg Med Chem. 2009 Dec 1;17(23):7884-93. doi: 10.1016/j.bmc.2009.10.032. Epub 2009 Oct 21.


Targeting the ubiquitin-proteasome system for cancer therapy.

Yang Y, Kitagaki J, Wang H, Hou DX, Perantoni AO.

Cancer Sci. 2009 Jan;100(1):24-8. doi: 10.1111/j.1349-7006.2008.01013.x. Epub 2008 Nov 24. Review.

Supplemental Content

Support Center